Nakashima K, Jindo T, Nomura M
Research Institute, Daiichi Seiyaku Co., Ltd., Tokyo, Japan.
Arzneimittelforschung. 1988 Jul;38(7A):1038-9.
The local tolerance of N2-[(N-acetylmuramoyl)- N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys (L18), muroctasin), a synthetic muramyl dipeptide derivative, was investigated in rabbits. One ml of MDP-Lys (L18) injection was administered into the dorsal subcutis in single dose or multiple doses. Pathological examination revealed moderate infiltration of inflammatory cells at the injection sites 2 days after the last injection, but there was a tendency for recovery from this change to occur by the 7th day after injection. In conclusion, the tissue lesion caused by MDP-Lys (L18) injection administered subcutaneously is slight and transient.